168 related articles for article (PubMed ID: 30944525)
1. Development of
Jung M; Won H; Shin MK; Oh MW; Shim S; Yoon I; Yoo HS
J Vet Sci; 2019 Mar; 20(2):e2. PubMed ID: 30944525
[TBL] [Abstract][Full Text] [Related]
2. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of the role of antibodies to Actinobacillus pleuropneumoniae serovar 1 and 15 in the protection provided by sub-unit and live streptomycin-dependent pleuropneumonia vaccines.
Tumamao JQ; Bowles RE; van den Bosch H; Klaasen HL; Fenwick BW; Blackall PJ
Aust Vet J; 2004 Dec; 82(12):773-80. PubMed ID: 15648941
[TBL] [Abstract][Full Text] [Related]
4. New trends in innovative vaccine development against Actinobacillus pleuropneumoniae.
Loera-Muro A; Angulo C
Vet Microbiol; 2018 Apr; 217():66-75. PubMed ID: 29615259
[TBL] [Abstract][Full Text] [Related]
5. Use of recombinant ApxIV in serodiagnosis of Actinobacillus pleuropneumoniae infections, development and prevalidation of the ApxIV ELISA.
Dreyfus A; Schaller A; Nivollet S; Segers RP; Kobisch M; Mieli L; Soerensen V; Hüssy D; Miserez R; Zimmermann W; Inderbitzin F; Frey J
Vet Microbiol; 2004 Apr; 99(3-4):227-38. PubMed ID: 15066725
[TBL] [Abstract][Full Text] [Related]
6. Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model.
Seo KW; Kim SH; Park J; Son Y; Yoo HS; Lee KY; Jang YS
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):102-12. PubMed ID: 23200821
[TBL] [Abstract][Full Text] [Related]
7. Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs.
Wu HC; Yeh PH; Hsueh KJ; Yang WJ; Chu CY
J Appl Microbiol; 2018 Jun; 124(6):1366-1376. PubMed ID: 29431246
[TBL] [Abstract][Full Text] [Related]
8. Positive role for rApxIVN in the immune protection of pigs against infection by Actinobacillus pleuropneumoniae.
Wang C; Wang Y; Shao M; Si W; Liu H; Chang Y; Peng W; Kong X; Liu S
Vaccine; 2009 Sep; 27(42):5816-21. PubMed ID: 19654060
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous detection of antibodies against Apx toxins ApxI, ApxII, ApxIII, and ApxIV in pigs with known and unknown Actinobacillus pleuropneumoniae exposure using a multiplexing liquid array platform.
Giménez-Lirola LG; Jiang YH; Sun D; Hoang H; Yoon KJ; Halbur PG; Opriessnig T
Clin Vaccine Immunol; 2014 Jan; 21(1):85-95. PubMed ID: 24226091
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of multicomponent recombinant vaccines against Actinobacillus pleuropneumoniae in mice.
Shao M; Wang Y; Wang C; Guo Y; Peng Y; Liu J; Li G; Liu H; Liu S
Acta Vet Scand; 2010 Sep; 52(1):52. PubMed ID: 20831818
[TBL] [Abstract][Full Text] [Related]
11. Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
Maas A; Meens J; Baltes N; Hennig-Pauka I; Gerlach GF
Vaccine; 2006 Nov; 24(49-50):7226-37. PubMed ID: 17027123
[TBL] [Abstract][Full Text] [Related]
12. Genetic and antigenic characteristics of ApxIIA and ApxIIIA from Actinobacillus pleuropneumoniae serovars 2, 3, 4, 6, 8 and 15.
To H; Nagai S; Iwata A; Koyama T; Oshima A; Tsutsumi N
Microbiol Immunol; 2016 Jul; 60(7):447-58. PubMed ID: 27211905
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of an indirect enzyme-linked immunosorbent assay (ELISA) for detection of antibodies to the Apx toxins of Actinobacillus pleuropneumoniae.
Nielsen R; van den Bosch JF; Plambeck T; Sørensen V; Nielsen JP
Vet Microbiol; 2000 Jan; 71(1-2):81-7. PubMed ID: 10665536
[TBL] [Abstract][Full Text] [Related]
14. An immunosorbent assay based on the recombinant ApxIa, ApxIIa, and ApxIIIa toxins of Actinobacillus pleuropneumoniae and its application to field sera.
Shin MK; Kang ML; Cha SB; Lee WJ; Sung JH; Yoo HS
J Vet Diagn Invest; 2011 Jul; 23(4):736-42. PubMed ID: 21908316
[TBL] [Abstract][Full Text] [Related]
15. Interference of outer membrane protein PalA with protective immunity against Actinobacillus pleuropneumoniae infections in vaccinated pigs.
van den Bosch H; Frey J
Vaccine; 2003 Sep; 21(25-26):3601-7. PubMed ID: 12922088
[TBL] [Abstract][Full Text] [Related]
16. [Acute toxicity and immunoprotection of recombinant apxI toxin of Actinobacillus pleuropneumoniae in mice].
Yan KX; Liu JJ; Zhou R; Wu B; Liu WH; Chen HC
Sheng Wu Gong Cheng Xue Bao; 2006 Jan; 22(1):65-70. PubMed ID: 16572842
[TBL] [Abstract][Full Text] [Related]
17. [Study on immunogenicity of the N-terminal polypeptide of RTX toxin I of Actinobacillus pleuropneumoniae].
Mei L; Zhou R; Lu HS; Bei WC; Liu WH; Lin LW; Hong WZ; Chen HC
Sheng Wu Gong Cheng Xue Bao; 2006 Jan; 22(1):39-45. PubMed ID: 16572838
[TBL] [Abstract][Full Text] [Related]
18. The N-terminal domain of RTX toxin ApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice.
Seah JN; Frey J; Kwang J
Infect Immun; 2002 Nov; 70(11):6464-7. PubMed ID: 12379729
[TBL] [Abstract][Full Text] [Related]
19. Cloning, expression, and characterization of TonB2 from Actinobacillus pleuropneumoniae and potential use as an antigenic vaccine candidate and diagnostic marker.
Liu J; Chen Y; Yuan F; Hu L; Bei W; Chen H
Can J Vet Res; 2011 Jul; 75(3):183-90. PubMed ID: 22210994
[TBL] [Abstract][Full Text] [Related]
20. Production of Apx toxins by field strains of Actinobacillus pleuropneumoniae and Actinobacillus suis.
Kamp EM; Vermeulen TM; Smits MA; Haagsma J
Infect Immun; 1994 Sep; 62(9):4063-5. PubMed ID: 8063425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
